Homology Medicines reports Q4 EPS (60c), consensus (50c)

Reports Q4 revenue $802,000, consensus $830,000. "We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome, and we anticipate initial data read-outs from both programs this year," said Albert Seymour, president and CEO of Homology Medicines. "Dosing of the first patient in the pheEDIT trial for PKU marked a key milestone for Homology, and the forthcoming data will represent the first gene editing data in PKU patients. We believe the continued interest in the juMPStart trial for Hunter syndrome underscores the impact a one-time gene therapy with potential to address both the peripheral and CNS disease manifestations could have for patients and their loved ones."